Topic issue on new treatments in bladder cancer J. A. Witjes Editorial Open access 20 February 2009 Pages: 285 - 287
The present and future burden of urinary bladder cancer in the world Martine PloegKatja K. H. AbenLambertus A. Kiemeney Topic Paper Open access 15 February 2009 Pages: 289 - 293
Economic aspects of bladder cancer: what are the benefits and costs? K. D. SievertB. AmendA. Stenzl Topic Paper Open access 07 March 2009 Pages: 295 - 300
Application of new technology in bladder cancer diagnosis and treatment Alvin C. GohSeth P. Lerner Topic Paper 22 February 2009 Pages: 301 - 307
Bladder cancer: new TUR techniques Daniel WilbyKay ThomasTimothy O’Brien Topic Paper 04 March 2009 Pages: 309 - 312
Experimental rat bladder urothelial cell carcinoma models Harm C. ArentsenKees HendricksenJ. Alfred Witjes Topic Paper Open access 15 February 2009 Pages: 313 - 317
Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo® working party J. Alfred WitjesKees HendricksenO. Nativ Topic Paper Open access 22 February 2009 Pages: 319 - 324
Updates in intravesical electromotive drug administration® of mitomycin-C for non-muscle invasive bladder cancer Savino Mauro Di StasiClaus Riedl Topic Paper 21 February 2009 Pages: 325 - 330
The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience LaMont J. BarlowJames M. McKiernanMitchell C. Benson Topic Paper 13 February 2009 Pages: 331 - 335
Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer Kees HendricksenAntoine G. van der HeijdenJ. Alfred Witjes Topic Paper Open access 13 February 2009 Pages: 337 - 342
Combination of BCG and interferon intravesical immunotherapy: an update Kenneth G. NeppleHoward A. AubertMichael A. O’Donnell Topic Paper 29 May 2009 Pages: 343 - 346
Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3) Richard E. HautmannBjoern G. VolkmerKilian Gust Topic Paper 25 March 2009 Pages: 347 - 351
Experimental animal model and RNA interference: a promising association for bladder cancer research Leonardo Oliveira ReisTiago Campos PereiraUbirajara Ferreira Review 13 February 2009 Pages: 353 - 361
Varicocele is associated with an increase of connective tissue of the pampiniform plexus vein wall Massimo IafrateAntonio GalfanoVincenzo Ficarra Original Article 22 November 2008 Pages: 363 - 369
TGFB1 gene polymorphism Leu10Pro (c.29T>C), prostate cancer incidence and quality of life in patients treated with brachytherapy Andreas MeyerThilo DörkStefan Machtens Original Article 28 November 2008 Pages: 371 - 377
The value of newborn urinary proteome analysis in the evaluation and management of ureteropelvic junction obstruction: a cost-effectiveness study Hrair-George O. Mesrobian Original Article 26 November 2008 Pages: 379 - 383
Extraperitoneal laparoscopic adenomectomy for benign prostatic hyperplasia Lin-Yu ZhouJun XiaoQiang Xuan Original Article 10 December 2008 Pages: 385 - 387
IL-10 −1082 G>A: a risk for prostate cancer but may be protective against progression of prostate cancer in North Indian cohort Pravin KesarwaniDinesh Kumar AhirwarRama D. Mittal Original Article 15 January 2009 Pages: 389 - 396
A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging Ulrich MehnertSönke BoyBrigitte Schurch Original Article 15 January 2009 Pages: 397 - 403
Impact of preoperative haemoglobin concentrations on the efficiency of KTP-laser vaporization of the prostate Stephan BuseChristian GilfrichMarkus Hohenfellner Original Article 15 January 2009 Pages: 405 - 409
Connexin45 expression in the human obstructed detrusor muscle Hubert JohnMichael WalchCaroline Maake Original Article 15 January 2009 Pages: 411 - 418